These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Diagnosis and Treatment of Acromegaly: An Update. Ershadinia N; Tritos NA Mayo Clin Proc; 2022 Feb; 97(2):333-346. PubMed ID: 35120696 [TBL] [Abstract][Full Text] [Related]
24. Growth hormone deficiency in treated acromegaly and active Cushing's syndrome. Formenti AM; Maffezzoni F; Doga M; Mazziotti G; Giustina A Best Pract Res Clin Endocrinol Metab; 2017 Feb; 31(1):79-90. PubMed ID: 28477735 [TBL] [Abstract][Full Text] [Related]
25. Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks. Höybye C Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101788. PubMed ID: 37308376 [TBL] [Abstract][Full Text] [Related]
26. Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Lin E; Wexler TL; Nachtigall L; Tritos N; Swearingen B; Hemphill L; Loeffler J; Biller BM; Klibanski A; Miller KK Clin Endocrinol (Oxf); 2012 Sep; 77(3):430-8. PubMed ID: 22315983 [TBL] [Abstract][Full Text] [Related]
27. Do all adults with growth hormone deficiency require growth hormone treatment? Brooke AM; Monson JP Ann Med; 2003; 35(6):419-24. PubMed ID: 14572166 [TBL] [Abstract][Full Text] [Related]
28. The consequences of growth hormone deficiency in adulthood, and the effects of growth hormone replacement. Christ ER; Carroll PV; Russell-Jones DL; Sönksen PH Schweiz Med Wochenschr; 1997 Aug; 127(35):1440-9. PubMed ID: 9297747 [TBL] [Abstract][Full Text] [Related]
29. Biomarkers of Acromegaly and Growth Hormone Action. Maffezzoni F; Porcelli T; Delbarba A; Pezzaioli L; Cappelli C; Ferlin A Protein Pept Lett; 2020; 27(12):1231-1245. PubMed ID: 32310036 [TBL] [Abstract][Full Text] [Related]
30. [Serum tumor marker levels during a 12-months growth hormone replacement therapy in patients with adult growth hormone deficiency]. Hubina E; Kovács L; Szabolcs I; Rimanóczy E; Czirják S; Góth M Orv Hetil; 2002 Mar; 143(12):601-5. PubMed ID: 11963397 [TBL] [Abstract][Full Text] [Related]
31. Long-term safety of growth hormone replacement therapy in survivors of cancer and tumors of the pituitary region. Bolier M; van der Lelij AJ; Janssens GO; van den Heuvel-Eibrink MM; Neggers SJCMM Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37043373 [TBL] [Abstract][Full Text] [Related]
32. Effect of long-term GH replacement therapy on cardiovascular outcomes in isolated GH deficiency compared with multiple pituitary hormone deficiencies: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults. van Bunderen CC; van den Dries CJ; Heymans MW; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML Eur J Endocrinol; 2014 Aug; 171(2):151-60. PubMed ID: 24801587 [TBL] [Abstract][Full Text] [Related]
33. Management of growth hormone deficiency in adults. Nilsson AG; Svensson J; Johannsson G Growth Horm IGF Res; 2007 Dec; 17(6):441-62. PubMed ID: 17629530 [TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates? van Bunderen CC; Olsson DS Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101835. PubMed ID: 37914564 [TBL] [Abstract][Full Text] [Related]
35. Recent developments in the therapy of acromegaly. Paisley AN; Trainer PJ Expert Opin Investig Drugs; 2006 Mar; 15(3):251-6. PubMed ID: 16503762 [TBL] [Abstract][Full Text] [Related]
36. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings. Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373 [TBL] [Abstract][Full Text] [Related]
37. Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients. Evran M; Sert M; Tetiker T BMC Endocr Disord; 2014 Dec; 14():97. PubMed ID: 25511633 [TBL] [Abstract][Full Text] [Related]
38. Growth hormone deficiency in treated acromegaly. Mazziotti G; Marzullo P; Doga M; Aimaretti G; Giustina A Trends Endocrinol Metab; 2015 Jan; 26(1):11-21. PubMed ID: 25434492 [TBL] [Abstract][Full Text] [Related]
39. Growth Hormone Excess: Implications and Management. Dhaneshwar S; Shandily S; Tiwari V Endocr Metab Immune Disord Drug Targets; 2023; 23(6):748-763. PubMed ID: 36237164 [TBL] [Abstract][Full Text] [Related]
40. Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment. Arlien-Søborg MC; Madsen MA; Dal J; Krusenstjerna-Hafstrøm T; Ringgaard S; Skou N; Høgild M; Jørgensen JOL Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651164 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]